Myeloid Leukemia, Philadelphia-Positive

Myeloid Leukemia, Philadelphia-Positive — Trials · CancerIndex

Clinical trials

Registered studies

17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7
Recruiting: 3
Ph III recruiting: 1
Growth YoY: —
Industry share: 43%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04925479	Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia	recruiting	Phase 1 / Phase 2	34	Novartis PharmaceuticalsINDUSTRY	14	Sep 25, 2026	clinicaltrials
NCT01746836	Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib	recruiting	Phase 2	50	M.D. Anderson Cancer CenterOTHER	1	Sep 16, 2026